Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 576

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1B
Chunk 576
---
2
     
    Nominating and Corporate Governance Committee Charter (incorporated by reference to Exhibit 99.2 to Form S-1/A filed December 14, 2023)
  
    99.3
     
    Compensation Committee Charter (incorporated by reference to Exhibit 99.3 to Form S-1/A filed December 14, 2023)
  
    99.4
     
    Corporate Governance Guidelines (incorporated by reference to Exhibit 99.4 to Form S-1/A filed December 14, 2023)
  
    99.6
     
    Related Person Transaction Policy and Procedures (incorporated by reference to Exhibit 99.6 to Form S-1/A filed December 14, 2023)

    ^
    Previously
    filed.
  
    +
    Denotes
    management contract or compensatory plan or arrangement.

74

TELOMIR
PHARMACEUTICALS, INC.

INDEX
TO FINANCIAL STATEMENTS

    Report of Independent Registered Public Accounting Firm (PCAOB Firm ID 106)
    F-1

    Report of Independent Registered Public Accounting Firm (PCAOB Firm ID
42)
    F-2

    Balance Sheets as of December 31, 2024 and 2023
    F-3

    Statements of Operations for the years ended December 31, 2024 and 2023
    F-4

    Statement of Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023
    F-5

    Statements of Cash Flows for the years ended December 31, 2024 and 2023
    F-6

    Notes to Financial Statements
    F-8

Report
of Independent Registered Public Accounting Firm

To
the Stockholders and the Board of Directors of:

Telomir
Pharmaceuticals, Inc.

Opinion
on the Financial Statements

We have audited the accompanying balance sheet of Telomir Pharmaceuticals, Inc. (the “Company”) as of December 31, 2024, the
related statements of operations, changes in stockholders’ equity and cash flows for the year then ended, and the related notes
(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of December 31,